SlowBull
The Business Brief TUESDAY, 1 SEPTEMBER 2026
← All stories
Markets

Ozempic Maker Novo Nordisk’s Investors Are Nervously Looking Into the Future

1 source ·1 article ·2h ago

Novo Nordisk’s chief executive, Mike Doustdar, is a year into a corporate turnaround. He says investors are still underestimating the promise of the company’s drugs.

Covered by 1 outlet

Nytimes 1

All coverage · 1 article

NYT Business ·2h ago

Ozempic Maker Novo Nordisk’s Investors Are Nervously Looking Into the Future

Novo Nordisk’s chief executive, Mike Doustdar, is a year into a corporate turnaround. He says investors are still underestimating the promise of the company’s drugs.